PBS listing of lenalidomide (Revlimid) as maintenance treatment for patients with multiple myeloma has been welcomed after a “frustratingly long” approvals process. Lenalidomide represents Australia’s first and only maintenance treatment specifically indicated and reimbursed for patients newly diagnosed with multiple myeloma (NDMM) who have undergone an autologous stem cell transplant (ASCT). It is already available ...
Lenalidomide now available on PBS for MM maintenance therapy
By Mardi Chapman
2 Apr 2020